No Data
No Data
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results From the Global Phase 2b Trial of Rademikibart in Patients With Moderate-to-Severe Asthma
SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the "Company"), a global clinical-stage biopharmaceutical
Sector Update: Health Care Stocks Retreating Late Afternoon
Health care stocks eased in late Wednesday afternoon trading, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each decreasing 0.1%. The iShares Biotechnology ETF (IBB
Sector Update: Health Care
Health care stocks ease in late Wednesday afternoon trading with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both decreasing 0.1%. The iShares Biotechnology ETF (IBB)
Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer
Connect Biopharma (CNTB) is terminating its in-license agreement for CBP-174, an antiallergic, with Pfizer (PFE), effective May, to optimize resources and extend its cash runway The company said Tuesd
Connect Biopharma Is Maintained at Buy by HC Wainwright & Co.
Connect Biopharma Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Connect Biopharma Hldgs, Raises Price Target to $8